Desmopressin Phagecon: Uses, Dosage & Side Effects

What Is Desmopressin Phagecon and What Is It Used For?

Desmopressin is a synthetic peptide that was first developed in 1968 and has since become one of the most widely prescribed medications in endocrinology and pediatric urology. It is a structural analogue of arginine vasopressin (AVP), the naturally occurring antidiuretic hormone (ADH) produced by the hypothalamus and released from the posterior pituitary gland. The key modification in desmopressin compared with natural vasopressin is the deamination of the cysteine residue at position 1 and substitution of L-arginine with D-arginine at position 8. These changes give desmopressin three clinically important advantages over natural vasopressin: a much longer duration of action (6–14 hours versus 1–2 hours), significantly enhanced antidiuretic potency (approximately 10 times greater), and virtually no vasopressor (blood vessel constricting) activity at therapeutic doses.

Desmopressin exerts its primary therapeutic effect by binding to vasopressin V2 receptors, which are located on the basolateral membrane of principal cells in the renal collecting ducts. When desmopressin binds to V2 receptors, it activates a cyclic AMP (cAMP)-mediated intracellular signaling cascade that leads to the insertion of aquaporin-2 (AQP2) water channels into the apical (luminal) membrane of the collecting duct cells. These aquaporin-2 channels allow water to move from the tubular lumen back into the hypertonic renal medullary interstitium, driven by the osmotic gradient maintained by the countercurrent multiplication system. This process dramatically increases water reabsorption and produces a concentrated, low-volume urine. The net clinical effect is a reduction in urine output by up to 50–70%, which is the basis for its use in diabetes insipidus and nocturnal enuresis.

In addition to its antidiuretic effects, desmopressin has a clinically important role in hemostasis (blood clotting). When administered intravenously or via concentrated nasal spray, desmopressin stimulates the release of von Willebrand factor (vWF) and coagulation factor VIII (FVIII) from endothelial cell storage sites (Weibel-Palade bodies). This property makes desmopressin valuable in the management of mild hemophilia A (where factor VIII levels are partially reduced) and von Willebrand disease type 1 (where von Willebrand factor is quantitatively reduced but qualitatively normal). In these conditions, desmopressin can transiently raise factor VIII and vWF levels by 2–5 fold, providing sufficient hemostatic coverage for minor surgical procedures or acute bleeding episodes.

Central Diabetes Insipidus

Central diabetes insipidus (CDI), recently renamed arginine vasopressin deficiency (AVP-D) by the Endocrine Society in 2022, is a condition characterized by insufficient production or secretion of vasopressin from the posterior pituitary gland. Without adequate vasopressin, the kidneys cannot concentrate urine, leading to the production of large volumes (3–20 liters per day) of dilute urine (polyuria) and compensatory excessive thirst and fluid intake (polydipsia). CDI can be caused by pituitary surgery, head trauma, tumors (particularly craniopharyngiomas), infiltrative diseases (sarcoidosis, histiocytosis), autoimmune hypophysitis, or may be idiopathic. Desmopressin is the treatment of choice for CDI and effectively replaces the missing hormone, reducing urine output to normal levels and allowing patients to maintain fluid balance. Treatment typically requires lifelong therapy in permanent CDI.

Primary Nocturnal Enuresis (Bedwetting)

Primary nocturnal enuresis (PNE) is involuntary urination during sleep in children aged 5 years and older who have never achieved sustained nighttime dryness. PNE affects approximately 15–20% of 5-year-olds, 5–10% of 7-year-olds, and 1–2% of teenagers. A significant proportion of these children have nocturnal polyuria, meaning they produce an abnormally large volume of urine during the night due to a blunted nocturnal rise in vasopressin secretion. Desmopressin is effective in this subgroup by reducing nighttime urine production to a volume that the bladder can accommodate. International guidelines, including those from NICE and the International Children’s Continence Society (ICCS), recommend desmopressin as a first-line pharmacological treatment for PNE when alarm therapy is not suitable or has not been effective. The oral lyophilisate formulation is often preferred for children as it dissolves quickly on the tongue without requiring water.

Nocturia in Adults

Nocturia is the complaint of waking one or more times during the night to urinate, and it is one of the most prevalent and bothersome lower urinary tract symptoms in adults, particularly in the elderly. When nocturia is caused by nocturnal polyuria (defined as nighttime urine volume exceeding 33% of 24-hour urine output), low-dose desmopressin can reduce nighttime urine production and the number of nocturnal voids. Clinical trials have demonstrated that desmopressin reduces nocturia episodes by approximately 50% compared with placebo. However, the risk of hyponatremia is higher in elderly patients, and careful patient selection, dose titration, and regular sodium monitoring are essential.

Mild Hemophilia A and Von Willebrand Disease Type 1

Desmopressin is used as a hemostatic agent in patients with mild hemophilia A (factor VIII activity ≥5%) and von Willebrand disease type 1 to cover minor surgical procedures, dental extractions, or menorrhagia. Before therapeutic use, a desmopressin challenge test (trial infusion) is recommended to confirm that the patient responds with an adequate rise in factor VIII and von Willebrand factor levels. Desmopressin is not effective in severe hemophilia A, von Willebrand disease type 2B (where it may worsen thrombocytopenia), or type 3 von Willebrand disease.

What Should You Know Before Taking Desmopressin Phagecon?

Contraindications

Desmopressin is contraindicated in several clinical situations where the drug’s antidiuretic effect could cause serious harm. Understanding these contraindications is essential for safe prescribing and use.

• Habitual or psychogenic polydipsia: Patients who habitually drink excessive amounts of fluid (defined as more than 40 mL/kg/24 hours or approximately 3 liters per day in adults) are at very high risk of life-threatening water intoxication and hyponatremia if they take desmopressin, because the drug prevents the kidneys from excreting the excess water.
• Known or suspected cardiac insufficiency requiring diuretic therapy: The water-retaining effect of desmopressin can exacerbate fluid overload and precipitate heart failure in patients with compromised cardiac function.
• Moderate to severe renal insufficiency: Desmopressin is primarily renally cleared, and impaired renal function (GFR <50 mL/min) increases the risk of drug accumulation and hyponatremia. Additionally, the antidiuretic effect depends on intact renal concentrating mechanisms, which may be impaired in advanced kidney disease.
• Known hyponatremia: Patients with serum sodium below the normal range must not take desmopressin, as the drug will further dilute the blood sodium concentration.
• Syndrome of inappropriate ADH secretion (SIADH): Desmopressin mimics and amplifies the effect of endogenous ADH, and is therefore contraindicated in patients with SIADH, which already involves excessive water retention.
• Hypersensitivity: Desmopressin must not be used in patients with known hypersensitivity to desmopressin or any of the excipients in the formulation.

Warnings and Precautions

The following precautions should be carefully observed during desmopressin therapy:

• Fluid restriction: Patients must be instructed to limit fluid intake to a minimum from 1 hour before taking desmopressin until at least 8 hours after administration. This means no unnecessary drinking during this period. Children should drink only enough to satisfy thirst; parents and caregivers must enforce this restriction carefully.
• Serum sodium monitoring: Baseline serum sodium should be measured before starting treatment. Serum sodium should be checked again within 3–7 days of starting treatment or adjusting the dose, and at regular intervals (at least every 3–6 months) during ongoing treatment. More frequent monitoring is required in elderly patients and in children.
• Intercurrent illness: Desmopressin should be temporarily discontinued during intercurrent illness with vomiting, diarrhea, or systemic infections (especially gastroenteritis), as fluid balance is difficult to control during acute illness and the risk of hyponatremia is increased.
• Elderly patients: Older adults are at increased risk of hyponatremia due to age-related changes in renal concentrating ability, reduced total body water, and concurrent use of medications that can affect sodium balance. The starting dose should be kept low and sodium levels monitored closely.
• Nasal congestion: If using the intranasal formulation, nasal congestion, rhinitis, or other conditions affecting nasal absorption may alter drug delivery. Patients should switch to oral formulations if nasal absorption is unreliable.

Pregnancy and Breastfeeding

Data from a limited number of pregnancies in women with diabetes insipidus treated with desmopressin have not shown increased risks of adverse pregnancy outcomes, including congenital malformations, miscarriage, or preterm birth. Animal reproductive studies have not demonstrated teratogenic effects. However, as with all medications during pregnancy, desmopressin should only be used when the expected benefit to the mother justifies the potential risk to the fetus. Diabetes insipidus can worsen during pregnancy due to increased metabolism of vasopressin by placental vasopressinase, and dose adjustments may be necessary. Blood pressure monitoring is recommended during desmopressin use in pregnancy.

Desmopressin is excreted into breast milk in very small quantities. Studies have shown that the amount of desmopressin that may be transferred to a nursing infant is far below the therapeutic dose. Desmopressin is considered compatible with breastfeeding at the doses used for diabetes insipidus. However, the decision to continue breastfeeding during desmopressin treatment should be made in consultation with your healthcare provider, taking into account the benefits of breastfeeding for the infant and the clinical benefit of desmopressin therapy for the mother.

How Does Desmopressin Phagecon Interact with Other Drugs?

Desmopressin is not metabolized by cytochrome P450 (CYP) hepatic enzymes, so traditional drug-drug interactions mediated through enzyme inhibition or induction are not expected. However, several medications can potentiate the antidiuretic effect of desmopressin, leading to an increased risk of water retention and hyponatremia. The following table summarizes the most clinically significant interactions.

Major Interactions

The most clinically significant interactions involve drugs that independently promote water retention or enhance ADH activity, creating a synergistic effect with desmopressin. Carbamazepine and oxcarbazepine are among the most concerning because they are well-known causes of SIADH (syndrome of inappropriate ADH secretion) in their own right. When combined with desmopressin, the risk of severe hyponatremia is substantially increased, and the combination should be avoided whenever possible. If concomitant use is unavoidable, serum sodium should be monitored at least weekly.

SSRIs present a similar concern because these antidepressants are among the most common causes of drug-induced hyponatremia, particularly in elderly women. The mechanism involves both inappropriate ADH release and increased renal sensitivity to ADH. When an SSRI is combined with desmopressin, the risk of hyponatremia may be synergistically increased. Clinicians prescribing both agents should ensure that patients are aware of the symptoms of hyponatremia (headache, nausea, confusion, lethargy, and in severe cases seizures) and should check serum sodium within the first week of co-administration and at regular intervals thereafter.

Minor Interactions

Several other medications may modestly enhance or be affected by desmopressin, although the clinical significance is generally lower. Thiazide diuretics, while not directly potentiating desmopressin’s antidiuretic effect, can independently cause hyponatremia and therefore add to the overall sodium-lowering risk. ACE inhibitors and angiotensin receptor blockers (ARBs) have been associated with rare cases of hyponatremia and should be noted when considering the patient’s overall risk profile. Glucocorticoids at high doses may attenuate the antidiuretic effect of desmopressin through their effect on free water clearance.

It is important to note that food can significantly reduce the oral absorption of desmopressin. Tablets and oral lyophilisates should be taken on an empty stomach, at least 30 minutes before or 2 hours after meals, to ensure consistent drug absorption and clinical effect. A standardized meal has been shown to reduce the area under the curve (AUC) of oral desmopressin by approximately 40%.

What Is the Correct Dosage of Desmopressin Phagecon?

Desmopressin dosing must be individualized for each patient based on the specific indication, the patient’s age, clinical response, and serum sodium levels. The principle of using the lowest effective dose is especially important with desmopressin to minimize the risk of hyponatremia. The following dosage guidelines are based on international clinical recommendations, but actual prescribed doses may vary based on the specific formulation and regional guidelines.

Adults

For central diabetes insipidus in adults, desmopressin is typically started at a low dose (0.1 mg orally three times daily) and gradually titrated upward based on the patient’s fluid balance, urine output, urine osmolality, and serum sodium levels. The goal is to achieve adequate urine concentration (reducing 24-hour urine volume to a comfortable level, typically 1.5–2.5 liters) without causing fluid overload or hyponatremia. Most adults with central DI require total daily oral doses of 0.2–1.2 mg, divided into two or three doses. The interindividual variation in dose requirement is considerable, reflecting differences in the degree of vasopressin deficiency and individual renal responsiveness.

For nocturia due to nocturnal polyuria, the recommended starting dose in adults under 65 years is 0.1 mg taken at bedtime. Fluid intake should be restricted from 1 hour before taking the tablet until at least 8 hours after (essentially until the next morning). The dose may be increased to 0.2 mg or 0.4 mg after at least one week if the initial dose does not provide adequate reduction in nighttime voids. Serum sodium should be checked at baseline, within 3–7 days of starting or dose adjustment, and at regular intervals during ongoing treatment. Lower doses (0.1 mg) are recommended as the starting and maintenance dose in women, who appear to be more sensitive to the antidiuretic effect of desmopressin.

Children

For primary nocturnal enuresis in children aged 5 years and older, the recommended starting dose is 0.2 mg (tablet) or 120 mcg (oral lyophilisate) taken at bedtime, at least 1 hour before sleep. The oral lyophilisate is placed on the tongue where it dissolves in seconds without the need for water, which is advantageous in the context of fluid restriction. If the initial dose does not achieve adequate dryness after 1–4 weeks, the dose may be increased to 0.4 mg (tablet) or 240 mcg (lyophilisate). Treatment courses should be limited to 3 months, after which a treatment-free period of at least 1 week should be observed to assess whether the child still needs medication.

For central diabetes insipidus in children, dosing is individualized based on the child’s age, weight, severity of vasopressin deficiency, and clinical response. Younger children typically require lower doses. Serum sodium monitoring is especially critical in pediatric patients because of their higher risk of hyponatremia and the potentially devastating consequences of hyponatremic seizures or cerebral edema in developing brains.

Elderly

Elderly patients (aged 65 years and older) are at significantly increased risk of desmopressin-induced hyponatremia due to several age-related physiological changes: reduced renal concentrating ability, lower total body water, decreased glomerular filtration rate, and frequent concurrent use of medications that affect sodium balance (diuretics, SSRIs, ACE inhibitors). For nocturia treatment in elderly patients, desmopressin should be started at the lowest available dose (0.1 mg or the equivalent lyophilisate), and serum sodium must be measured before treatment, within 3 days of starting, after 1 week, after 1 month, and regularly thereafter (at least every 3–6 months). The Endocrine Society and the EMA have issued specific cautions regarding desmopressin use in elderly patients for the nocturia indication.

Missed Dose

If you miss a dose of desmopressin for diabetes insipidus, take it as soon as you remember unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a forgotten one. If you forget your bedtime dose for bedwetting or nocturia, do not take it later during the night, as this could affect your fluid balance the following day. Simply resume your normal dosing schedule the next evening.

Overdose

Overdose of desmopressin leads to excessive water retention and dilutional hyponatremia. Symptoms of overdose include headache, nausea, vomiting, abdominal cramps, weight gain, drowsiness, confusion, and in severe cases seizures, loss of consciousness, and cerebral edema. Treatment of overdose involves immediate discontinuation of desmopressin, strict fluid restriction, and in severe cases (serum sodium <120 mmol/L or neurological symptoms), administration of hypertonic saline (3% NaCl) under close medical supervision in a hospital setting. Correction of hyponatremia should be gradual (no more than 10–12 mmol/L per 24 hours) to avoid the risk of osmotic demyelination syndrome. In case of suspected overdose, seek emergency medical care immediately.

What Are the Side Effects of Desmopressin Phagecon?

Like all medicines, desmopressin can cause side effects, although not everyone will experience them. The overall safety profile of desmopressin has been established through more than 50 years of clinical use and extensive clinical trial data. The side effects are generally dose-dependent and closely related to the drug’s pharmacological action of promoting water retention. The most important safety concern is hyponatremia, which is largely preventable with appropriate fluid restriction and sodium monitoring.

The side effect profile varies somewhat depending on the route of administration. Oral and sublingual formulations tend to have fewer systemic side effects than intranasal or intravenous formulations. The frequency categories used below are based on data from clinical trials, post-marketing surveillance, and spontaneous adverse event reports.

Hyponatremia is the most clinically significant adverse effect of desmopressin and warrants detailed discussion. It occurs because desmopressin promotes water retention without sodium retention, leading to a dilutional decrease in serum sodium concentration. Risk factors for desmopressin-induced hyponatremia include excessive fluid intake, elderly age (over 65 years), low baseline serum sodium, concomitant use of medications that impair water excretion (SSRIs, carbamazepine, thiazide diuretics), and renal impairment. In clinical trials for nocturnal enuresis, clinically significant hyponatremia (serum sodium <130 mmol/L) occurred in approximately 1–5% of patients, although this rate was substantially lower when proper fluid restriction was observed.

Symptoms of mild hyponatremia include headache, nausea, loss of appetite, and mild confusion. Moderate hyponatremia may cause vomiting, muscle cramps, weakness, and drowsiness. Severe hyponatremia (serum sodium <120 mmol/L) can result in seizures, loss of consciousness, respiratory arrest, and brain herniation. If any symptoms of hyponatremia develop, desmopressin should be stopped immediately, fluid intake should be restricted, and medical attention should be sought urgently. The vast majority of hyponatremia cases are preventable through adherence to fluid restriction guidelines and regular sodium monitoring.

The side effect profile of intranasal desmopressin includes local effects such as nasal congestion, rhinitis, and occasional nosebleeds. Conditions that affect the nasal mucosa (common cold, allergic rhinitis, nasal polyps) can unpredictably alter drug absorption, leading to either subtherapeutic levels or overdosing. For this reason, oral or sublingual formulations are generally preferred for chronic use.

How Should You Store Desmopressin Phagecon?

Proper storage of desmopressin is important to maintain the stability and effectiveness of the medication. Desmopressin is a peptide molecule that can be degraded by heat, moisture, and prolonged light exposure. The specific storage requirements vary by formulation, but general principles apply to all forms.

• Tablets: Store below 25°C (77°F) in the original packaging. Protect from moisture. Keep the container tightly closed. Do not remove tablets from the blister pack until ready to take them.
• Oral lyophilisate (melt tablets): These are particularly sensitive to moisture. Store below 25°C in the original blister packaging. Do not push the tablet through the foil; instead, peel back the foil carefully to expose the tablet immediately before placing it on the tongue. Handle with dry hands only.
• Nasal spray: Store upright at 2–25°C (36–77°F). Once opened, use within 4 weeks. The spray device should be primed before first use according to the manufacturer’s instructions.
• Solution for injection: Store in a refrigerator at 2–8°C (36–46°F). Do not freeze. Protect from light. For single use only.
• Keep out of reach of children: Store all desmopressin formulations where children cannot access them. Accidental ingestion by a child who does not need the medication could cause serious hyponatremia.
• Check expiration date: Do not use desmopressin after the expiry date printed on the packaging. The expiration date refers to the last day of that month.
• Do not freeze: Freezing can damage the peptide structure and render the medication ineffective.

When traveling with desmopressin, keep the medication in your hand luggage to avoid temperature extremes in the cargo hold. If traveling to hot climates, consider using an insulated bag. Airport security X-ray screening will not damage the medication. Carry a copy of your prescription or a doctor’s letter confirming your need for the medication, particularly when traveling internationally.

What Does Desmopressin Phagecon Contain?

Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients. Desmopressin Phagecon contains desmopressin acetate as the active substance. Below is a detailed breakdown of the typical composition.

Active Ingredient

The active substance is desmopressin acetate, also known as 1-deamino-8-D-arginine vasopressin (DDAVP). Desmopressin is a synthetic nonapeptide with the molecular formula C₄₆H₆₄N₁₄O₁₂S₂ and a molecular weight of 1069.2 daltons (as the free base). It differs from natural arginine vasopressin by two modifications: deamination of the N-terminal cysteine and substitution of L-arginine with D-arginine at position 8. These modifications confer increased antidiuretic potency, prolonged duration of action, and minimal vasopressor activity.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Desmopressin Phagecon tablets are white, round, biconvex tablets. They are available in strengths of 0.1 mg and 0.2 mg. Tablets are typically supplied in blister packs of 30 or 100 tablets. Not all pack sizes may be marketed in every country. The oral lyophilisate formulation, where available, appears as a white, round, flat tablet designed to dissolve on the tongue. It is supplied in individually sealed blister cavities to protect from moisture.

Important Notes on Excipients

Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take the tablet formulation containing lactose monohydrate. Alternative formulations (such as the oral lyophilisate, which typically uses gelatin and mannitol instead of lactose) may be suitable. Always inform your pharmacist or doctor of any known intolerances.